Key result
Clinic blood pressure measurements were not consistently inferior to ambulatory BP in discriminating ESKD risk (HR 1.5; 95% CI 1.3-1.8 per 0.1 BP index increase) in children with CKD.
Why the study?
Are clinic blood pressure measurements inferior to ambulatory blood pressure monitoring in discriminating the risk of adverse outcomes in children with CKD?
Cohort (n=513)
Are clinic blood pressure measurements inferior to ambulatory blood pressure monitoring in discriminating the risk of adverse outcomes in children with CKD?
Hazard Ratio: 1.5 (95% CI 1.3–1.8)
Clinic blood pressure measurements taken in a protocol-driven setting are not consistently inferior to ambulatory blood pressure monitoring for discriminating the risk of left ventricular hypertrophy and ESKD in children with CKD.
Protocol-driven clinic BP may suffice for risk stratification in pediatric CKD; leaves open whether ambulatory monitoring adds incremental value.
Background and objectives Our objective was to determine whether clinic BPs (taken at either a single visit or two sequential visits) are inferior to ambulatory BPs in their ability to discriminate risk of adverse outcomes in children with CKD. Design, setting, participants, & measurements We included 513 participants of the CKD in Children Study who had clinic BPs and 24-hour ambulatory BP monitoring performed during similar timeframes. Predictors of interest were systolic BPs taken at a single visit or two repeated visits within a 1-year period compared with mean wake and sleep systolic ambulatory BPs. Outcomes were left ventricular hypertrophy and ESKD. We determined the ability for each BP parameter to provide risk discrimination using c statistics. Results During mean follow-up of 3.5 years, 123 participants developed ESKD. In cross-sectional unadjusted analysis, every 0.1 increase in systolic BP index was associated with a 2.0 times higher odds of left ventricular hypertrophy (95% confidence interval, 1.5 to 2.8) by clinic BPs versus 1.8 times higher odds (95% confidence interval, 1.3 to 2.4) by ambulatory wake BP. The c statistic was highest for clinic BP ( c =0.65; 95% confidence interval, 0.58 to 0.73) but similar to ambulatory wake BP ( c =0.64; 95% confidence interval, 0.57 to 0.71) for the discrimination of left ventricular hypertrophy. In longitudinal unadjusted analysis, every 0.1 increase in systolic BP index was associated with a higher risk of ESKD using repeated clinic (hazard ratio, 1.5; 95% confidence interval, 1.3 to 1.8) versus ambulatory wake BP (hazard ratio, 1.6; 95% confidence interval, 1.3 to 2.0). Unadjusted c statistics were the same for wake ( c =0.61; 95% confidence interval, 0.56 to 0.67) and clinic systolic BPs ( c =0.61; 95% confidence interval, 0.55 to 0.66) for discriminating risk of ESKD. Conclusions Clinic BPs taken in a protocol-driven setting are not consistently inferior to ambulatory BP in the discrimination of BP-related adverse outcomes in children with CKD.
No takes yet. Share an insight, caveat, or question.
Ku et al. (2018) conducted a cohort in Chronic Kidney Disease (CKD) (n=513). Clinic blood pressure measurements vs. Ambulatory blood pressure measurements was evaluated on ESKD (HR 1.5, 95% CI 1.3 to 1.8). Clinic blood pressure measurements were not consistently inferior to ambulatory BP in discriminating ESKD risk (HR 1.5; 95% CI 1.3-1.8 per 0.1 BP index increase) in children with CKD.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: